March 2025
1. RASH BG, Ramdas KN, Agafonova N, Naioti E, et al
   Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
   Nat Med. 2025 Mar 10. doi: 10.1038/s41591-025-03559.
   

   >> Share

   
   February 2025
2. MULLER A, Sullivan J, Schwarzer W, Wang M, et al
   High-efficiency base editing in the retina in primates and human tissues.
   Nat Med. 2025;31:490-501.
   

   >> Share

   
   December 2024
3. O'LEARY K
   Stem cells reverse type 1 diabetes.
   Nat Med. 2024;30:3393.
   

   >> Share

   
   November 2024
4. 
   HIV-1 remission following stem cell transplant without CCR5Delta32 mutation.
   Nat Med. 2024 Nov 6. doi: 10.1038/s41591-024-03365.
   

   >> Share

   
   October 2024
5. SVENDSEN SP, Svendsen CN
   Cell therapy for neurological disorders.
   Nat Med. 2024;30:2756-2770.
   

   >> Share

   
   
6. DIEZ-DIEZ M, Ramos-Neble BL, de la Barrera J, Silla-Castro JC, et al
   Unidirectional association of clonal hematopoiesis with atherosclerosis development.
   Nat Med. 2024;30:2857-2866.
   

   >> Share

   
   September 2024
7. SAEZ-CIRION A, Mamez AC, Avettand-Fenoel V, Nabergoj M, et al
   Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells.
   Nat Med. 2024 Sep 2. doi: 10.1038/s41591-024-03277.
   

   >> Share

   
   
8. CHEN X, Huang Y, Huang L, Huang Z, et al
   A brain cell atlas integrating single-cell transcriptomes across human brain regions.
   Nat Med. 2024;30:2679-2691.
   

   >> Share

   
   June 2024
9. CHEN YB, Mohty M, Zeiser R, Teshima T, et al
   Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
   Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03016.
   

   >> Share

   
   May 2024
10. ZINTER MS, Dvorak CC, Mayday MY, Reyes G, et al
    Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation.
    Nat Med. 2024 May 23. doi: 10.1038/s41591-024-02999.
    

    >> Share

    
    
11. KELLY K, Bloor AJC, Griffin JE, Radia R, et al
    Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease.
    Nat Med. 2024 May 22. doi: 10.1038/s41591-024-02990.
    

    >> Share

    
    
12. HOUOT R, Bachy E, Cartron G, Gros FX, et al
    Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
    Nat Med. 2024 May 14. doi: 10.1038/s41591-024-03053.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share